Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

To further our strategic development plan, preparing to initiate the open-label tanruprubart FORWARD study, measuring pharmacokinetics, pharmacodynamics, early efficacy in week 1, and safety in up to ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83% ...

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83%) ...

Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma CRANBERRY TOWNSHIP, PENNSYLVANIA / ACCESS Newswire / May 9, 2025 / Jabez Biosc ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder.